- Home
- ADC vs MIRM Comparison
ADC vs MIRM Comparison
Compare ADC & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADC | MIRM |
|---|---|---|
| Founded | 1971 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.2B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ADC | MIRM |
|---|---|---|
| Price | $69.19 | $94.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 12 |
| Target Price | $77.75 | ★ $154.00 |
| AVG Volume (30 Days) | ★ 1.6M | 571.5K |
| Earning Date | 10-20-2026 | 11-03-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $718,398,000.00 | $19,138,000.00 |
| Revenue This Year | $16.93 | $37.65 |
| Revenue Next Year | $12.82 | $21.04 |
| P/E Ratio | $47.11 | ★ N/A |
| Revenue Growth | ★ 16.42 | N/A |
| 52 Week Low | $64.34 | $63.23 |
| 52 Week High | $82.08 | $130.00 |
Technical Indicators
Market Signals| Indicator | ADC | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | 59.57 |
| Support Level | $64.38 | $87.38 |
| Resistance Level | $70.91 | $98.34 |
| Average True Range (ATR) | 1.10 | 4.28 |
| MACD | 0.21 | 0.96 |
| Stochastic Oscillator | 66.99 | 68.65 |
Price Performance
Historical ComparisonAbout ADC Agree Realty Corporation
Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-tenants. The Company is mainly in the business of acquiring, developing and managing retail real estate. Some of its properties in the portfolio include Walmart, 7-Eleven, Wawa, Gerber Collision and others.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.